287 related articles for article (PubMed ID: 31791278)
21. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
23. Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma.
Elshahoubi A; Alnassan A; Sultan I
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e152-e154. PubMed ID: 30608490
[TBL] [Abstract][Full Text] [Related]
24. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
25. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Bhatia S; Krailo MD; Chen Z; Burden L; Askin FB; Dickman PS; Grier HE; Link MP; Meyers PA; Perlman EJ; Rausen AR; Robison LL; Vietti TJ; Miser JS
Blood; 2007 Jan; 109(1):46-51. PubMed ID: 16985182
[TBL] [Abstract][Full Text] [Related]
26. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Felgenhauer JL; Nieder ML; Krailo MD; Bernstein ML; Henry DW; Malkin D; Baruchel S; Chuba PJ; Sailer SL; Brown K; Ranganathan S; Marina N
Pediatr Blood Cancer; 2013 Mar; 60(3):409-14. PubMed ID: 23065953
[TBL] [Abstract][Full Text] [Related]
28. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].
Peng RJ; Sun XF; Xiang XJ; Zhen ZJ; Ling JY; Tong GL; Xia Y; Xu GC; Jiang WQ
Ai Zheng; 2009 Dec; 28(12):1304-9. PubMed ID: 19958626
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH
J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232
[TBL] [Abstract][Full Text] [Related]
31. Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
Chin M; Yokoyama R; Sumi M; Okita H; Kawai A; Hosono A; Koga Y; Sano H; Watanabe H; Ozaki T; Mugishima H;
Pediatr Blood Cancer; 2020 May; 67(5):e28194. PubMed ID: 32077253
[TBL] [Abstract][Full Text] [Related]
32. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Paulussen M; Ahrens S; Lehnert M; Taeger D; Hense HW; Wagner A; Dunst J; Harms D; Reiter A; Henze G; Niemeyer C; Göbel U; Kremens B; Fölsch UR; Aulitzky WE; Voûte PA; Zoubek A; Jürgens H
Ann Oncol; 2001 Nov; 12(11):1619-30. PubMed ID: 11822764
[TBL] [Abstract][Full Text] [Related]
33. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease.
Ahmed SK; Robinson SI; Okuno SH; Rose PS; Issa Laack NN
Am J Clin Oncol; 2014 Oct; 37(5):423-9. PubMed ID: 23388557
[TBL] [Abstract][Full Text] [Related]
34. Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.
Spunt SL; McCarville MB; Kun LE; Poquette CA; Cain AM; Brandao L; Pappo AS
J Pediatr Hematol Oncol; 2001 Feb; 23(2):93-8. PubMed ID: 11216713
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
[TBL] [Abstract][Full Text] [Related]
36. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
[TBL] [Abstract][Full Text] [Related]
37. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
Paulino AC; Nguyen TX; Mai WY; Teh BS; Wen BC
Pediatr Blood Cancer; 2007 Aug; 49(2):145-8. PubMed ID: 16732580
[TBL] [Abstract][Full Text] [Related]
38. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
Argon A; Basaran M; Yaman F; Dizdar Y; Sakar B; Camlica H; Bavbek SE; Ozger H; Darendeliler E; Onat H
Jpn J Clin Oncol; 2004 Nov; 34(11):667-72. PubMed ID: 15613556
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Womer RB; Daller RT; Fenton JG; Miser JS
Eur J Cancer; 2000 Jan; 36(1):87-94. PubMed ID: 10741300
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
